SCHEMBL2814036

SCHEMBL2814036

C1CCC(Nc2nc3c4c(n[nH]c4n2)CCN3)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
PDE4A P27815 1/20 0.35
HTR2A P28223 2/20 0.34
HTR2C P28335 1/20 0.34
CTSK P43235 3/20 0.33
CTSS P25774 2/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CDK1 P06493 2/20 0.33
CDK4 P11802 2/20 0.33
CCNB1 P14635 2/20 0.33
CCNA2 P20248 2/20 0.33
CCND1 P24385 2/20 0.33
CDK2 P24941 2/20 0.33
CCNA1 P78396 2/20 0.33
LRRK2 Q5S007 1/20 0.33
PAK1 Q13153 1/20 0.32
ROCK1 Q13464 1/20 0.32
CCNE1 P24864 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2812119 0.93 KDM4E (0.36) KDM4EGAAPDE4AHTR2AHTR2C
SCHEMBL2816669 0.85 CDK4 (0.38) CDK1CDK4CCNB1CCNA2CCND1
SCHEMBL2810592 0.68 TUBB4A (0.38) KDM4ECCNA2CDK2CCNA1
SCHEMBL3296576 0.66 PDE4A (0.64) KDM4EGAAPDE4ACTSKCTSS
SCHEMBL2814039 0.64 KDM4E (0.39) KDM4EGAAPDE4ACTSKCTSS
SCHEMBL12645185 0.58 PDE4A (0.55) KDM4EGAAPDE4ACTSK
SCHEMBL18163295 0.58 PDE4A (0.76) KDM4EGAAPDE4ACTSK
SCHEMBL6640516 0.58 PDE4A (0.55) KDM4EGAAPDE4A
SCHEMBL21260553 0.58 PDE4A (0.76) KDM4EGAAPDE4ACTSK
SCHEMBL20402878 0.58 PDE4A (0.82) KDM4EGAAPDE4ACTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 KDM4E 2749/4885GAA 1908/4885PDE4A 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.